Rep. Marjorie Taylor Greene Buys Novo Nordisk A/S (NYSE:NVO) Stock

Key Points

• Representative Marjorie Taylor Greene purchased shares of Novo Nordisk A/S valued between $15,001 and $50,000 on August 19th, as disclosed in a filing on August 20th.
• Novo Nordisk's stock has shown a 12-month range with a low of $45.05 and a high of $139.74, and the company recently reported $0.97 earnings per share, exceeding estimates.
• The firm plans to pay a semi-annual dividend of $0.4119 per share to shareholders of record on August 18th, representing a yield of 240.0% with a payout ratio of 22.53%.

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on August 20th, the Representative disclosed that they had bought between $15,001 and $50,000 in Novo Nordisk A/S stock on August 19th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 7/15/2025.
• Purchased $1,001 - $15,000 in shares of Palantir Technologies NASDAQ: PLTR on 7/15/2025.
• Purchased $1,001 - $15,000 in shares of Tractor Supply NASDAQ: TSCO on 6/17/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 6/17/2025.
• Sold $1,001 - $15,000 in shares of lululemon athletica NASDAQ: LULU on 6/17/2025.
• Purchased $1,001 - $15,000 in shares of Netflix NASDAQ: NFLX on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 6/6/2025.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded down $0.63 during trading hours on Monday, hitting $56.35. 16,131,337 shares of the company's stock were exchanged, compared to its average volume of 29,651,820. The stock's 50-day moving average is $62.16 and its 200-day moving average is $69.00. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The stock has a market cap of $251.60 billion, a price-to-earnings ratio of 15.48, a price-to-earnings-growth ratio of 1.98 and a beta of 0.63. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be issued a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is presently 22.53%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NVO. Barclays reissued an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Wall Street Zen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. BNP Paribas raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. BNP Paribas Exane raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price on the stock in a research note on Wednesday, August 13th. Finally, HSBC lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price on the stock. in a research note on Thursday, July 31st. Three research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Hold" and an average target price of $81.00.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds have recently modified their holdings of the business. North Star Investment Management Corp. grew its holdings in shares of Novo Nordisk A/S by 18.2% during the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock worth $1,440,000 after buying an additional 3,200 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Novo Nordisk A/S by 6.0% during the first quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company's stock worth $58,316,000 after buying an additional 47,804 shares in the last quarter. Stanley Laman Group Ltd. bought a new position in shares of Novo Nordisk A/S during the first quarter worth about $390,000. Dover Advisors LLC bought a new position in shares of Novo Nordisk A/S during the first quarter worth about $505,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Novo Nordisk A/S by 15.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 261,243 shares of the company's stock worth $18,141,000 after buying an additional 35,329 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.